Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

1.7K
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
1.7K
Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists01:30

Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists

812
Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function.
812
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

573
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
573
Atherosclerosis IV: Nursing Management01:23

Atherosclerosis IV: Nursing Management

559
Nursing management for a patient with arteriosclerosis involves a comprehensive approach focusing on lifestyle modification, disease monitoring, education, and symptomatic care. Here is an overview of effective nursing strategies:Assessment and Monitoring: Initial and ongoing assessments are crucial. Nurses must document the patient's medical history, including any hypertension, diabetes, hyperlipidemia, and other cardiovascular diseases. Assessments also cover family history and lifestyle...
559
Atherosclerosis II: Clinical Manifestations and Diagnostic Tests01:27

Atherosclerosis II: Clinical Manifestations and Diagnostic Tests

728
Atherosclerosis is a progressive disorder that leads to the thickening and narrowing of arterial walls due to plaque buildup. This condition can cause various symptoms depending on the arteries affected:Coronary Artery Disease (CAD): This condition affects the coronary arteries and may lead to chest pain (angina), shortness of breath (dyspnea), heart attacks, and other heart disease symptoms.Cerebrovascular Disease: This affects blood flow to the brain, causing transient ischemic attacks (TIAs)...
728
Drug Toxicity: Risk factors01:24

Drug Toxicity: Risk factors

147
Adverse Drug Reactions (ADRs) are potential complications that arise during pharmacotherapy, influenced by multiple risk factors. Age plays a significant role; both neonates and the elderly are at heightened risk due to their respective immature and diminished metabolic and elimination processes. Gender also impacts ADRs, with females experiencing a 1.5 to 1.7-fold greater risk than males, which may be linked to pharmacokinetic, pharmacodynamic, and hormonal differences. Notably, neonates, the...
147

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Methamphetamine Use and Psychiatric Morbidity in Sri Lanka: Sociodemographic Insights from a Tertiary Care Clinic.

Indian journal of psychological medicine·2026
Same author

Outcome of first episode and relapsing patients with schizophrenia presenting to a tertiary care hospital in Sri Lanka: A prospective one year follow up study.

Asian journal of psychiatry·2026
Same author

PCR-based SNP genotyping: A comprehensive comparison of methods for affordable and accurate detection of class IV mutations.

Analytica chimica acta·2025
Same author

Genotyping SNPs and Indels: A method to improve the scope and sensitivity of High-Resolution melt (HRM) analysis based applications.

Clinica chimica acta; international journal of clinical chemistry·2024
Same author

What Women Want: Mental Health in the Context of Violence Against Women in Sri Lanka-A Qualitative Study of Priorities and Capacities for Care.

Violence against women·2024
Same author

Achievements and challenges in psychiatric education and training in Sri Lanka.

BJPsych international·2023

Related Experiment Video

Updated: Mar 23, 2026

Evaluation of the Cognitive Performance of Hypertensive Patients with Silent Cerebrovascular Lesions
07:30

Evaluation of the Cognitive Performance of Hypertensive Patients with Silent Cerebrovascular Lesions

Published on: April 23, 2021

3.5K

Simvastatin-induced cognitive dysfunction: two case reports.

Chathurie Suraweera1, Varuni de Silva2, Raveen Hanwella2

  • 1University Psychological Medicine Unit, National Hospital of Sri Lanka, Colombo, Sri Lanka. dr.chathurie@gmail.com.

Journal of Medical Case Reports
|April 7, 2016
PubMed
Summary

Simvastatin, used for high cholesterol, may cause cognitive impairment in some patients. Cognitive deficits observed in two cases reversed after discontinuing the drug, suggesting a potential link.

Keywords:
Cognitive deficitsMemory lossSimvastatin

More Related Videos

A Mouse Model for Vascular Cognitive Impairment and Dementia Based on Needle-guided Asymmetric Bilateral Common Carotid Artery Stenosis
05:12

A Mouse Model for Vascular Cognitive Impairment and Dementia Based on Needle-guided Asymmetric Bilateral Common Carotid Artery Stenosis

Published on: November 22, 2024

1.6K
Dual-Task Stroop Paradigm for Detecting Cognitive Deficits in High-Functioning Stroke Patients
07:42

Dual-Task Stroop Paradigm for Detecting Cognitive Deficits in High-Functioning Stroke Patients

Published on: December 16, 2022

3.9K

Related Experiment Videos

Last Updated: Mar 23, 2026

Evaluation of the Cognitive Performance of Hypertensive Patients with Silent Cerebrovascular Lesions
07:30

Evaluation of the Cognitive Performance of Hypertensive Patients with Silent Cerebrovascular Lesions

Published on: April 23, 2021

3.5K
A Mouse Model for Vascular Cognitive Impairment and Dementia Based on Needle-guided Asymmetric Bilateral Common Carotid Artery Stenosis
05:12

A Mouse Model for Vascular Cognitive Impairment and Dementia Based on Needle-guided Asymmetric Bilateral Common Carotid Artery Stenosis

Published on: November 22, 2024

1.6K
Dual-Task Stroop Paradigm for Detecting Cognitive Deficits in High-Functioning Stroke Patients
07:42

Dual-Task Stroop Paradigm for Detecting Cognitive Deficits in High-Functioning Stroke Patients

Published on: December 16, 2022

3.9K

Area of Science:

  • Neuroscience
  • Pharmacology

Background:

  • Simvastatin is widely used to manage hypercholesterolemia and reduce vascular risk.
  • The relationship between cholesterol, statins, and cognitive function is complex and debated.
  • Emerging evidence suggests statins may cause or exacerbate cognitive impairment.

Observation:

  • Two cases of Asian patients (32-year-old male, 54-year-old female) developed cognitive deficits after initiating simvastatin.
  • The observed cognitive deficits were distinct but clearly present in both individuals.
  • Symptoms resolved after the cessation of simvastatin treatment.

Findings:

  • Simvastatin use was temporally associated with the onset of cognitive dysfunction in these patients.
  • Reversal of cognitive deficits upon drug discontinuation supports a causal link.
  • This suggests simvastatin can induce or worsen cognitive impairment.

Implications:

  • Clinicians should consider the potential for simvastatin-induced cognitive dysfunction.
  • Monitoring cognitive function is crucial for patients prescribed simvastatin, especially those with pre-existing cognitive issues.
  • Further research is needed to elucidate the mechanisms and prevalence of statin-associated cognitive effects.